Antev
London, United Kingdom· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Antev is a clinical stage biotech developing Teverelix as first in market product for high CV risk prostate cancer patients & patients with first Acute Urinary Retention (AUR) episode due to enlarged prostate
Small Molecules